A restricted number of ESMO Merit Travel Grants to the ESMO Gynaecological Cancers Congress 2024 are available, upon application, to first author (= presenter) who submit abstracts considered to be deserving of recognition. Candidates must be ESMO Members under the age of 40. Selection will be ma...
A restricted number of ESMO Merit Travel Grants to the ESMO Gynaecological Cancers Congress 2024 are available, upon application, to first author (= presenter) who submit abstracts considered to be deserving of recognition. Candidates must be ESMO Members under the age of 40. Selection will be ma...
参考来源: ESMO Gynaecological Cancers Congress 2024 - ESMO Gynaecological Cancers Congress 2024 - ABSTRACT SUBMISSION (ctimeetingtech.com) — END — 汇集最新最全的肿瘤资讯 欢迎关注CCMTV临床频道·肿瘤之音!
2024年ESMO妇科癌症大会(ESMO Gynaecological Cancers Congress 2024)于6月20-22日在佛罗伦萨举行。根据这项会议的报道,在叶酸受体α(FRalpha)高、铂耐药卵巢癌患者中进行的III期MIRASOL(GOG3045/ENGOT-ov55)试验的事后分析显示,与研究者选择的化疗相比,即使是那些需要调整治疗剂量的患者,使用抗体-药物偶联物(ADC)mirv...
6月20—22日,全球妇科肿瘤学领域享有盛誉的年度盛会——欧洲肿瘤学会妇科肿瘤年会(ESMO Gynaecological Cancers Congress 2024)在意大利佛罗伦萨隆重召开。来自全球100多个国家和地区的专家学者汇聚大会,公布妇科肿瘤领域前沿高质量研究成果。 我院放疗科张勇教授、马姗姗副主任医师团队通过壁报形式展示了最新研究成果:一项前瞻...
2024 年 ESMO 妇科癌症大会,ESMO Gynaecological Cancers Congress 2024,该大会将于 2024 年 6 月 20 日至 22 日在意大利佛罗伦萨举行,也可在线参加。本届大会将采用创新的 LIVE Plus 形式,为代表们提供大量的思想交流机会。 您将有机会亲身了解实践中的挑战和争议,与同行进行集思广益,并探索进一步发展职业生涯的...
3. Liu K, et al. Concurrent chemoradiotherapy and immunotherapy for locally advanced cervical cancer: A cost-effectiveness analysis based on the KEYNOTE-A18 trial. ESMO Gynaecological Cancers Congress 2024, Abstract 27P
(D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) for newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm): updated results from DUO-O. ESMO Gynaecological Cancers Congress 2024, Abstract 43...
2024年ESMO妇科癌症大会(ESMO Gynaecological Cancers Congress 2024)于6月20-22日在佛罗伦萨举行。根据这项会议的报道,在叶酸受体α(FRalpha)高、铂耐药卵巢癌患者中进行的III期MIRASOL(GOG3045/ENGOT-ov55)试验的事后分析显示,与研究者选择的化疗相比,即使是那些需要调整治疗剂量的患者,使用抗体-药物偶联物(ADC)mirv...
III evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of endometrial/ovarian carcinosarcoma after at least one line of platinum-based chemotherapy, preliminary results. ESMO Gynaecological Cancers Congress 2024, Abstract 34O...